Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with b

[News]

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

More... (http://www.news-medical.net/news/20100209/Denosumab-exhibits-superiority-over-Zometa-in-treatment-of-prostate-cancer-men-with-bone-metastases.aspx)